Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic Heart Failure: A Phase II Danish Multicentre Study

Table 4

Mesenchymal stem cell trials in patients with chronic ischemic heart disease.

Reference	Number of patients	Cell type	Design	Delivery route	Endpoints
Allogeneic
Hare et al. 2012 [22]	30	MSC	RO	IM	Safety and feasible
Perin et al. 2015 [23]	60	MSC	RSCT	IM	Safety and feasible
Kastrup et al. 2017 [12]	10	ASC	Open	IM	Safety and feasible
Hare et al. 2017 [24]	37	MSC	Open	IM	Safety and efficacy
Autologous
Chen et al. 2006 [25]	22	MSC	Open	IC	Improved LVEF, exercise capacity, and symptoms
Mohyeddin-Bonab et al. 2007 [26]	8	MSC	Open	IC	Improved LVEF, infarct size, and symptoms
Katritsis et al. 2007 [19]	5	MSC	Open	IC	Not arrhythmogenic
Williams et al. 2011 [27]	4	MSC	Open	IM	Reduced LV dimensions and infarct size
Friis et al. 2011 [7]	31	MSC	Open	IM	Improved LVEF, exercise capacity, and symptoms
Lasala et al. 2011 [28]	10	MSC	Open	IC	Increased LVEF
Mathiasen et al. 2014 [10]	60	MSC	PPCT	IM	Safe, improved LVEF, and increased myocardial mass
Qayyum et al. 2017 [11]	60	ASC	PPCT	IM	Safe. Tendency toward improved exercise capacity

IC: intracoronary; IM: intramyocardial; LV: left ventricular; LVEF: left ventricular ejection fraction; RO: randomised open study; RPCT: randomised placebo controlled trial; RSCT: randomised sham controlled trial.